Yesintek, a Stelara biosimilar, received FDA approval for IBD, plaque psoriasis, and psoriatic arthritis, with a launch expected in late 2025. Clinical trials confirmed Yesintek's equivalence to ...
Elena Wolff-Holz, M.D., Global Head Clinical Development, Biocon Biologics said,"The positive results from this Phase 3 study reaffirm the quality and therapeutic equivalence of YESINTEK compared to ...
BRIDGEWATER, N.J., and BENGALURU, India, March 7, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results